Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $160.00 at Guggenheim

Apogee Therapeutics (NASDAQ:APGE) had its price target raised by Guggenheim from $130.00 to $160.00 in a research report report published on Tuesday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other equities research analysts have also recently commented on the stock. Stifel Nicolaus set a $133.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, January 6th. Royal Bank Of Canada dropped their price target on shares of Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating for the company in a research report on Monday, March 2nd. Truist Financial began coverage on shares of Apogee Therapeutics in a research note on Tuesday, March 17th. They issued a “hold” rating and a $83.00 price objective for the company. Wedbush raised their price objective on shares of Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, March 3rd. Finally, Stephens began coverage on shares of Apogee Therapeutics in a research note on Tuesday, December 16th. They set an “overweight” rating and a $95.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.43.

Apogee Therapeutics Stock Performance

NASDAQ:APGE opened at $73.00 on Tuesday. The stock has a 50-day simple moving average of $71.16 and a two-hundred day simple moving average of $63.95. The firm has a market capitalization of $5.07 billion, a PE ratio of -17.30 and a beta of 1.39. Apogee Therapeutics has a 52-week low of $26.20 and a 52-week high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.02. Equities analysts forecast that Apogee Therapeutics will post -3.09 earnings per share for the current fiscal year.

Insider Transactions at Apogee Therapeutics

In other news, Director Fairmount Funds Management Llc sold 1,750,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the sale, the director directly owned 298,647 shares in the company, valued at approximately $22,786,766.10. This represents a 85.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $74.78, for a total transaction of $1,495,600.00. Following the completion of the transaction, the chief executive officer directly owned 1,152,987 shares of the company’s stock, valued at approximately $86,220,367.86. The trade was a 1.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,839,700 shares of company stock worth $140,118,083 in the last three months. Insiders own 42.77% of the company’s stock.

Institutional Investors Weigh In On Apogee Therapeutics

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Apogee Therapeutics by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after purchasing an additional 694 shares during the period. Millennium Management LLC raised its holdings in Apogee Therapeutics by 100.0% during the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock valued at $9,726,000 after buying an additional 130,164 shares during the period. Creative Planning bought a new stake in Apogee Therapeutics in the second quarter worth $392,000. Handelsbanken Fonder AB lifted its position in Apogee Therapeutics by 13.3% in the second quarter. Handelsbanken Fonder AB now owns 8,500 shares of the company’s stock worth $369,000 after buying an additional 1,000 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Apogee Therapeutics by 7.4% during the second quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock worth $1,203,000 after buying an additional 1,907 shares during the period. 79.04% of the stock is owned by institutional investors.

Key Stories Impacting Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase 2 Part A data for zumilokibart (APG777) showed durable maintenance and deepening of responses with every‑3‑month and every‑6‑month dosing (e.g., 75% and 85% maintained EASI‑75), supporting the drug’s infrequent‑dosing value proposition. GlobeNewswire: 52‑Week Data
• Positive Sentiment: Analysts reacted quickly with multiple buy ratings and big price‑target increases (Guggenheim, Canaccord, Citi, BTIG), lifting sentiment that the program could support late‑stage development or M&A interest. Benzinga: Analyst Upgrades
• Positive Sentiment: Investor write‑ups and media coverage highlighted the favorable maintenance results and potential next catalysts (Part B induction data in Q2 and possible phase‑3 start in H2 2026), sustaining bullish narrative. Seeking Alpha: Strong Buy / Catalyst Summary
• Neutral Sentiment: Company held a conference call/webcast to review the Part A 52‑week data, providing more transparency on durability and safety that investors can digest for modeling. GlobeNewswire: Conference Call
• Neutral Sentiment: Short‑interest notices in the feed show zero reported short shares (likely a data artifact); they do not provide meaningful evidence of positioning pressure.
• Negative Sentiment: Apogee announced a proposed $300 million underwritten public offering (with up to $45M option), which raises dilution risk and often triggers selling pressure after a rally — the most likely proximate cause of the intraday pullback. GlobeNewswire: Offering Announcement

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.